<DOC>
	<DOCNO>NCT01573182</DOCNO>
	<brief_summary>The purpose study determine whether vaccination stem cell donor Zostavax reduce rate Herpes Zoster reactivations transplant recipient . The clinical hypothesis : 1 ) Zostavax give stem cell donor induce protective VZV specific T cell proliferation allogeneic stem cell transplant recipient transfer recipient ; 2 ) donor vaccination Zostavax safe transplant recipient measure viral load measurement polymerase chain reaction assay ( PCR ) time stem cell donation .</brief_summary>
	<brief_title>Herpes Zoster Vaccine Bone Marrow Transplant Donors</brief_title>
	<detailed_description>Infection major cause morbidity death among haemopoietic stem cell transplantation patient ( HSCTs ) . Beyond initial post-transplant ( BMT ) phase neutropenia , common infection cytomegalovirus ( CMV ) fungal infection . Another common infection BMT patient increase risk varicella-zoster virus ( VZV ) ( primary varicella herpes zoster ) . VZV infection control specific T cell response impair post stem cell transplant . Heat inactivate VZV vaccine show halve incidence herpes zoster adult BMT patient undergo autologous transplantation . Clinical protection correlate vitro CD4 T-cell proliferation response varicella-zoster virus . Being live vaccine , attenuate VZV ( herpes zoster ( HZ ) vaccine contraindicate within 24 month allogeneic HSCT . However , prim donor T-cells herpes zoster vaccine may feasible alternative . One possible complication transfer live virus vaccinate donor immunocompromised stem cell transplant recipient . Normal donor donate HLA match sibling vaccinate Varivax vaccine prior donation . Stem cell product assess time donation evidence VZV PCR response vaccination T cell proliferation . Transfer VZV proliferative response transplant recipient assess VZV specific T cell proliferation 3 , 6 , 9 12 month post transplantation .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Allogeneic HSCT Recipientdonor pair Donor age 50 year Recipients donor willing recruit pair study Recipients undergo myeloablative non myeloablative non T cell deplete , allogeneic stem cell transplant HLA identical 1 HLA antigen mismatch sibling . Lack informed consent Inability recruit donor recipient pair Autologous transplant Contraindication Zostavax donor Donor age &lt; 50 year Recipient VZV immunoglobulin G ( IgG ) negative pretransplantation , Donor VZV IgG negative Pregnancy donor randomisation Inability follow study protocol ( donor recipient ) Malignancy immunosuppression HSC donor Expected HSCT within 30 42 day</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Zostavax</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>VZV vaccination</keyword>
	<keyword>Allogeneic haemopoietic stem cell transplantation</keyword>
</DOC>